Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
septiembre 26, 2026
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.